Myocardial infarction associated with erenumab: a case report
| Autor: | Justine Perino, Virginie Corand, Elise Laurent, Hélène Théophile, Ghada Miremont‐Salamé, Antoine Pariente, Jean‐Laurent Colas, Thierry Couffinhal, Francesco Salvo |
|---|---|
| Přispěvatelé: | Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], Polyclinique Bordeaux Nord Aquitaine, Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases, Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), INSERM, U1034, Centre de Pharmacovigilance [CHU Bordeaux] (CP), Centre de la douleur de Bordeaux (CDB) |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
[SDV] Life Sciences [q-bio]
drug safety migraine disorder [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system [SDV]Life Sciences [q-bio] pharmacovigilance adverse event [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology case report Pharmacology (medical) calcitonin gene-related peptide |
| Zdroj: | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Wiley, In press, ⟨10.1002/phar.2706⟩ Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2022, Online ahead of print. ⟨10.1002/phar.2706⟩ |
| ISSN: | 0277-0008 |
| DOI: | 10.1002/phar.2706⟩ |
| Popis: | International audience; Background: Monoclonal antibodies acting on the calcitonin gene related peptide or its receptor (CGRP-mabs) are novel drugs for resistant migraine prophylaxis. As CGRP-mabs cause inhibition of vasodilatation, their use is reserved to patients with no recent history of cardiovascular diseases. We report a case of myocardial infarction associated with erenumab.Case: A 57-year-old woman with a familial history of coronaropathy, was first treated with erenumab 70 mg for 6 months, then increased to 140 mg. Almost five months after, the patient presented chest pain, increased troponin and abnormal electrocardiogram. A myocardial infarction without coronarography abnormality was diagnosed through MRI.Conclusion: Further evidence is needed to assess the risk of myocardial infarction in patients treated with a CGRP-mab. In patients over 40 years of age, the risk of coronary or cardiovascular events should be assessed using risk tables or algorithms to take into account cardiovascular risk factors. This may be complemented by appropriate exams to measure the burden of coronary atherosclerosis, if necessary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text